Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur Sells 5,209 Shares

Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $7.70, for a total value of $40,109.30. Following the transaction, the chief operating officer now directly owns 129,690 shares in the company, valued at approximately $998,613. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Daniel Lesueur also recently made the following trade(s):

• On Thursday, October 3rd, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The shares were sold at an average price of $7.68, for a total value of $40,005.12.
• On Wednesday, September 4th, Daniel Lesueur sold 8,137 shares of Health Catalyst stock. The stock was sold at an average price of $7.58, for a total value of $61,678.46.

Health Catalyst Trading Up 7.4 %

Shares of NASDAQ:HCAT traded up $0.61 on Thursday, reaching $8.86. 808,341 shares of the company were exchanged, compared to its average volume of 562,764. Health Catalyst, Inc. has a 1-year low of $5.42 and a 1-year high of $11.41. The company has a 50-day moving average of $8.01 and a 200-day moving average of $7.11. The firm has a market cap of $535.76 million, a price-to-earnings ratio of -5.91 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.04. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The company had revenue of $75.90 million for the quarter, compared to analyst estimates of $74.96 million. During the same period in the prior year, the business posted ($0.21) earnings per share. The firm’s revenue for the quarter was up 3.7% compared to the same quarter last year. As a group, analysts forecast that Health Catalyst, Inc. will post -0.35 earnings per share for the current year.

Institutional Investors Weigh In On Health Catalyst

A number of institutional investors and hedge funds have recently modified their holdings of the company. Quest Partners LLC acquired a new position in Health Catalyst during the third quarter worth $34,000. Nisa Investment Advisors LLC grew its holdings in Health Catalyst by 461.0% in the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock valued at $41,000 after purchasing an additional 5,232 shares during the last quarter. Quarry LP increased its position in shares of Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after buying an additional 2,610 shares in the last quarter. nVerses Capital LLC acquired a new position in shares of Health Catalyst during the 3rd quarter worth $59,000. Finally, Perfromance Wealth Partners LLC purchased a new stake in shares of Health Catalyst in the 2nd quarter worth about $64,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Royal Bank of Canada raised their target price on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research report on Thursday. Piper Sandler lowered their price objective on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research report on Monday, August 26th. Stephens dropped their price target on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a report on Friday, October 4th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $11.64.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.